SCYNEXIS (SCYX) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
19 May, 2026Opening remarks and agenda
The meeting was called to order with board members, executive officers, and the auditor present.
The agenda was limited to one proposal as set forth in the proxy statement.
Specific resolutions to be voted on
The sole proposal was to approve an amendment to the certificate of incorporation to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, and to decrease the number of authorized shares.
The exact ratio for the reverse split would be determined at the board's discretion.
Corporate governance
Quorum was established with proxies representing 64.9% of outstanding shares.
Scott Sukenick was appointed Inspector of Election.
No additional proposals were filed by shareholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from SCYNEXIS
- Q1 2026 featured a major acquisition, $21.3M net loss, and cash runway extended to mid-2029.SCYX
Q1 202611 May 2026 - Resale registration for 87M shares from a private placement; proceeds only from warrant exercises.SCYX
Registration filing1 May 2026 - Key votes include board elections, auditor ratification, and major share authorization changes.SCYX
Proxy filing1 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and capital increase.SCYX
Proxy filing30 Apr 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing27 Apr 2026 - Shareholders will vote on director elections, compensation, equity plan, and capital structure changes.SCYX
Proxy filing20 Apr 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing17 Apr 2026 - Acquisition of SCY-770 for ADPKD offers major commercial potential and no royalty obligations.SCYX
M&A announcement2 Apr 2026 - SCY-247 advances as a potent antifungal with strong clinical data and significant market potential.SCYX
investor presentation4 Mar 2026